Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Accounts Payables (2019 - 2025)

Burning Rock Biotech has reported Accounts Payables over the past 7 years, most recently at $5.7 million for Q4 2025.

  • For Q4 2025, Accounts Payables rose 22.27% year-over-year to $5.7 million; the TTM value through Dec 2025 reached $5.7 million, up 22.27%, while the annual FY2025 figure was $5.8 million, 26.02% up from the prior year.
  • Accounts Payables for Q4 2025 was $5.7 million at Burning Rock Biotech, up from $4.8 million in the prior quarter.
  • Over five years, Accounts Payables peaked at $15.4 million in Q1 2022 and troughed at $2.5 million in Q4 2023.
  • A 5-year average of $6.1 million and a median of $4.9 million in 2025 define the central range for Accounts Payables.
  • Biggest five-year swings in Accounts Payables: surged 102.92% in 2022 and later tumbled 77.76% in 2023.
  • Year by year, Accounts Payables stood at $9.9 million in 2021, then dropped by 27.4% to $7.2 million in 2022, then plummeted by 64.98% to $2.5 million in 2023, then soared by 87.29% to $4.7 million in 2024, then grew by 22.27% to $5.7 million in 2025.
  • Business Quant data shows Accounts Payables for BNR at $5.7 million in Q4 2025, $4.8 million in Q3 2025, and $4.5 million in Q2 2025.